期刊
HUMAN BRAIN MAPPING
卷 40, 期 18, 页码 5424-5442出版社
WILEY
DOI: 10.1002/hbm.24782
关键词
Alzheimer's disease; amyloid; mild cognitive impairment; neuroinflammation; neuropathology; PET; tau
资金
- Alzheimer's Disease Neuroimaging Initiative
- European Commission IMI2 fund
- Alzheimer's Research UK
- National Institute for Health Research
- AVID Radiopharmaceuticals
- Medical Research Council
- Curium
- Invicro
- Life Molecular Imaging
- Glaxo Wellcome R D
- CHDI Foundation
- Edmond and Lilly Safra Foundation
- Michael J Fox Foundation
- Foundation for the National Institutes of Health
- Canadian Institutes of Health Research
- Transition Therapeutics
- Takeda Pharmaceutical Company
- Servier
- Piramal Imaging
- Pfizer Inc.
- Novartis Pharmaceuticals Corporation
- Neurotrack Technologies
- NeuroRx Research
- Meso Scale Diagnostics, LLC.
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- IXICO Ltd.
- GE Healthcare
- Fujarebio US
- Genentech, Inc.
- F. Hoffmann-La Roche Ltd.
- EuroImmun
- Eli Lilly and Company
- Elan Pharmaceuticals, Inc.
- Eisai, Inc.
- Cogstate
- CereSpir, Inc.
- Bristol-Myers Squibb Compan
- Biogen
- BioClinica, Inc.
- Araclon Biotech
- Alzheimer's Drug Discovery Foundation
- Alzheimer's Association
- AbbVie
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- Department of Defense [W81XWH-12-2-0012]
- National Institutes of Health [U01 AG024904]
Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of the disease. Molecular imaging with positron emission tomography (PET) allows for the in vivo visualisation and tracking of pathophysiological changes in AD and MCI. PET is a very promising methodology for differential diagnosis and novel targets of PET imaging might also serve as biomarkers for disease-modifying therapeutic interventions. This review provides an overview of the current status and applications of in vivo molecular imaging of AD pathology, specifically amyloid, tau, and microglial activation. PET imaging studies were included and evaluated as potential biomarkers and for monitoring disease progression. Although the majority of radiotracers showed the ability to discriminate AD and MCI patients from healthy controls, they had various limitations that prevent the recommendation of a single technique or tracer as an optimal biomarker. Newer research examining amyloid, tau, and microglial PET imaging in combination suggest an alternative approach in studying the disease process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据